Royal DSM announced Oct. 2 the completion of its acquisition of Erber Group for an enterprise value of 980 million euros.

DSM said the transaction — which excludes two smaller units in the Erber Group — is expected to be earnings enhancing in the first year upon completion. The acquisition of Erber Group was first announced June 12, 2020.

Through the transaction, DSM acquired Erber Group’s Biomin and Romer Labs. Biomin -- Erber Group’s specialty animal nutrition and health business -- specializes primarily in mycotoxin risk management and gut health performance management, whereas the Romer Labs business focuses on food and feed safety diagnostic solutions. Both will expand DSM’s range of higher-value-added specialty solutions, the company said.

The acquisition of Biomin further strengthens DSM’s expertise as a provider of animal health and nutrition solutions for farm productivity and sustainability, with an emphasis on emission reduction, feed consumption efficiency and better water and land use, DSM said.

Romer Labs also complements DSM’s human nutrition and health offering to customers in the food and beverage market segments, according to the announcement.

Royal DSM is a global, purpose-led, science-based company active in nutrition, health and sustainable living. DSM delivers solutions for human and animal nutrition, personal care and aroma, medical devices, green products and applications and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about 10 billion euros and have approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam.